Assenagon Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $601M | Sell |
501,025
-1,049,209
| -68% | -$1.07B | 0.75% | 20 |
|
|
2026
Q1 | $1.43B | Buy |
1,550,234
+1,208,510
| +354% | +$1.23B | 2.16% | 7 |
|
|
2025
Q4 | $367M | Sell |
341,724
-231,222
| -40% | -$221M | 0.51% | 33 |
|
|
2025
Q3 | $437M | Sell |
572,946
-908,085
| -61% | -$676M | 0.6% | 29 |
|
|
2025
Q2 | $1.15B | Buy |
1,481,031
+765,010
| +107% | +$594M | 1.71% | 7 |
|
|
2025
Q1 | $591M | Sell |
716,021
-384,369
| -35% | -$320M | 0.99% | 16 |
|
|
2024
Q4 | $850M | Sell |
1,100,390
-65,306
| -6% | -$54.1M | 1.37% | 13 |
|
|
2024
Q3 | $1.03B | Buy |
1,165,696
+584,866
| +101% | +$526M | 1.9% | 10 |
|
|
2024
Q2 | $526M | Buy |
580,830
+64,869
| +13% | +$51.9M | 1.17% | 17 |
|
|
2024
Q1 | $401M | Buy |
515,961
+229,319
| +80% | +$163M | 0.95% | 18 |
|
|
2023
Q4 | $167M | Sell |
286,642
-188,298
| -40% | -$110M | 0.44% | 42 |
|
|
2023
Q3 | $255M | Buy |
474,940
+18,079
| +4% | +$9.32M | 0.79% | 16 |
|
|
2023
Q2 | $214M | Buy |
456,861
+318,391
| +230% | +$134M | 0.74% | 17 |
|
|
2023
Q1 | $47.6M | Sell |
138,470
-444,678
| -76% | -$150M | 0.17% | 114 |
|
|
2022
Q4 | $213M | Buy |
583,148
+179,865
| +45% | +$63.8M | 0.77% | 24 |
|
|
2022
Q3 | $130M | Buy |
403,283
+310,845
| +336% | +$98.5M | 0.5% | 41 |
|
|
2022
Q2 | $30M | Sell |
92,438
-32,983
| -26% | -$9.9M | 0.11% | 174 |
|
|
2022
Q1 | $35.9M | Sell |
125,421
-506,371
| -80% | -$130M | 0.1% | 175 |
|
|
2021
Q4 | $175M | Buy |
631,792
+335,703
| +113% | +$85.1M | 0.51% | 37 |
|
|
2021
Q3 | $68.4M | Buy |
296,089
+122,224
| +70% | +$30.2M | 0.22% | 82 |
|
|
2021
Q2 | $39.9M | Sell |
173,865
-230,251
| -57% | -$46.3M | 0.14% | 132 |
|
|
2021
Q1 | $75.5M | Buy |
404,116
+19,333
| +5% | +$3.78M | 0.31% | 60 |
|
|
2020
Q4 | $65M | Buy |
384,783
+266,505
| +225% | +$39.8M | 0.28% | 72 |
|
|
2020
Q3 | $17.5M | Buy |
118,278
+105,706
| +841% | +$16.4M | 0.1% | 139 |
|
|
2020
Q2 | $2.06M | Sell |
12,572
-118,379
| -90% | -$18.2M | 0.01% | 584 |
|
|
2020
Q1 | $18.2M | Buy |
130,951
+113,558
| +653% | +$15.6M | 0.15% | 114 |
|
|
2019
Q4 | $2.29M | Sell |
17,393
-407,473
| -96% | -$47.2M | 0.01% | 408 |
|
|
2019
Q3 | $47.5M | Buy |
424,866
+401,683
| +1,733% | +$44.7M | 0.32% | 68 |
|
|
2019
Q2 | $2.57M | Sell |
23,183
-813,478
| -97% | -$95.8M | 0.02% | 455 |
|
|
2019
Q1 | $109M | Sell |
836,661
-141,343
| -14% | -$17.2M | 1.02% | 19 |
|
|
2018
Q4 | $113M | Buy |
+978,004
| New | +$109M | 1.28% | 11 |
|
|
2017
Q4 | – | Sell |
-136,517
| Closed | -$11.7M | – | 726 |
|
|
2017
Q3 | $11.7M | Buy |
+136,517
| New | +$11.2M | 0.11% | 166 |
|
|
2017
Q1 | – | Sell |
-216,322
| Closed | -$15.9M | – | 288 |
|
|
2016
Q4 | $15.9M | Buy |
+216,322
| New | +$16.1M | 0.3% | 80 |
|
Other funds holding LLY
SC
ONB
GIM
WAM
CRM
VNIM
Assenagon Asset Management's LLY Position: Q2 2026 in Review
Assenagon Asset Management reduced its Eli Lilly (LLY) stake by 68% in Q2 2026, selling an estimated $1.07B and leaving 501,025 shares worth $601M. The position accounts for 0.75% of the portfolio, ranked #20.
Assenagon Asset Management first reported a position in LLY in Q4 2016 and has held it in 33 quarters since. The position peaked at $1.43B in Q1 2026. 1,123 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Assenagon Asset Management held 501,025 shares of Eli Lilly worth $601M as of Q2 2026.
- Assenagon Asset Management sold 1,049,209 Eli Lilly shares in Q2 2026, an estimated $1.07B.
- Eli Lilly made up 0.75% of Assenagon Asset Management's portfolio in Q2 2026, its #20 holding.
- Assenagon Asset Management first reported a position in Eli Lilly in Q4 2016 and has held it in 33 quarters since.
- Assenagon Asset Management's Eli Lilly position peaked at $1.43B in Q1 2026.
- 1,123 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.